B2M and acute lymphoblastic leukemia: To determine whether MHC-I was necessary for the treatment's effectiveness, we knocked out the B2m gene in BCR-ABL1+ B-ALL cells using CRISPR/Cas9, confirming MHC-I loss by flow cytometry (Figure 6N).